FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
EIRS/483s

Linghai ZhanWang Records Show CGMP Violations

FDA warns Chinas Linghai ZhanWang Biotechnology Co. about CGMP violations in its manufacturing of over-the-counter drugs.

latest-news-card-1
Human Drugs

Positive Data on Pfizer/Arvinas Breast Cancer Study

Pfizer and Arvinas announce positive topline results from a clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in certain adults w...

latest-news-card-1
Human Drugs

FDA Rejects All Mid-Link Technology Data

FDA tells Chinas Mid-Link Technology Testing Co. it is rejecting all data from all studies conducted by the company until it provides a substantive re...

Animal Drugs

Clinical Researchers Plead Guilty to Fraud

Two clinical research facility owners plead guilty in Florida federal court to conspiracy to commit wire fraud in connection with their work on two cl...

latest-news-card-1
Human Drugs

FDA Warns 6 Firms on Unapproved Fat-Dissolving Drugs

FDA warns six companies that they are marketing unapproved fat-dissolving drugs.

latest-news-card-1
Human Drugs

Sydnexis NDA Accepted for Pediatric Myopia

FDA accepts a Sydnexis NDA for SYD-101 (topical low-dose atropine) for treating progression of pediatric myopia.dr

latest-news-card-1
Human Drugs

Top Device Science Official Leaves FDA

CDRH chief scientist and deputy Center director Doug Kelly abruptly resigns after less than five years at the agency.

Medical Devices

Beckman Coulter 510(k) Cleared for Clinical Analyzer

FDA clears a Beckman Coulter Diagnostics 510(k) for its DxC 500i Clinical Analyzer.

latest-news-card-1
FDA General

FDA Taps Jim Traficant as Chief of Staff

FDA names former business consultant Jim Traficant as chief of staff where he will oversee and lead the agencys major initiatives.

latest-news-card-1
Human Drugs

Mineralys Nets Positive Data in Hypertension Drug Studies

Mineralys Therapeutics reports positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials assessing lorundrostat...